CA2466033A1 - Methode de traitement de troubles lies a un taux de cholesterol eleve - Google Patents

Methode de traitement de troubles lies a un taux de cholesterol eleve Download PDF

Info

Publication number
CA2466033A1
CA2466033A1 CA002466033A CA2466033A CA2466033A1 CA 2466033 A1 CA2466033 A1 CA 2466033A1 CA 002466033 A CA002466033 A CA 002466033A CA 2466033 A CA2466033 A CA 2466033A CA 2466033 A1 CA2466033 A1 CA 2466033A1
Authority
CA
Canada
Prior art keywords
composition
compound
alkyl
hydroxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002466033A
Other languages
English (en)
Inventor
Shutsung Liao
Ching Song
Qing Dai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2466033A1 publication Critical patent/CA2466033A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne une méthode destinée à traiter des troubles liés à un taux de cholestérol élevé. Cette méthode consiste à administrer à un sujet nécessitant un traitement un composé de formule (I). L'invention concerne également des procédés, des nécessaires, des combinaisons et des compositions qui sont utilisés pour traiter des troubles chez un sujet lorsqu'un activateur du récepteur alpha X du foie est indiqué, par exemple pour traiter une maladie liée à un taux de cholestérol élevé.
CA002466033A 2001-11-08 2002-11-08 Methode de traitement de troubles lies a un taux de cholesterol eleve Abandoned CA2466033A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34802001P 2001-11-08 2001-11-08
US60/348,019 2001-11-08
PCT/US2002/035900 WO2003039480A2 (fr) 2001-11-08 2002-11-08 Methode de traitement de troubles lies a un taux de cholesterol eleve

Publications (1)

Publication Number Publication Date
CA2466033A1 true CA2466033A1 (fr) 2003-05-15

Family

ID=23366328

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002466033A Abandoned CA2466033A1 (fr) 2001-11-08 2002-11-08 Methode de traitement de troubles lies a un taux de cholesterol eleve

Country Status (5)

Country Link
EP (1) EP1450816A4 (fr)
JP (1) JP2005508368A (fr)
CA (1) CA2466033A1 (fr)
TW (1) TW200300078A (fr)
WO (1) WO2003039480A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (fr) 2004-10-25 2006-05-04 Virginia Commonwealth University Oxysterol sulfate nucleaire, regulateur homeostatique du cholesterol agissant puissamment dans le traitement de l'hypercholesterolemie, de l'hyperlipidemie et de l'atherosclerose
US7923573B2 (en) 2004-10-27 2011-04-12 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
CA2668661A1 (fr) 2006-11-13 2008-05-29 Novartis Ag Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp
CA2769203A1 (fr) 2009-07-29 2011-02-03 University Of Chicago Agonistes du recepteur x du foie
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
BR112014005373B1 (pt) * 2011-09-08 2022-04-19 Sage Therapeutics, Inc Compostos esteróides neuroativos, composições e usos destes
EP3865135A3 (fr) * 2013-03-13 2021-11-03 Sage Therapeutics, Inc. Stéroïdes neuroactifs destinés à l'utilisation thérapeutique
EP2968369B1 (fr) 2013-03-13 2018-08-29 Sage Therapeutics, Inc. Stéroïdes neuroactifs et leurs procédés d'utilisation
JP2016193835A (ja) * 2013-09-04 2016-11-17 学校法人常翔学園 核内受容体肝臓ｘ受容体アゴニスト
TWI816417B (zh) 2013-12-24 2023-09-21 維吉尼亞聯邦大學 氧化膽固醇硫酸鹽（ｏｃｓ）之用途
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
SI3319612T1 (sl) 2015-07-06 2021-11-30 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
MX2020011449A (es) 2015-07-06 2022-02-28 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK3436022T3 (da) 2016-04-01 2022-06-20 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse heraf
WO2017193046A1 (fr) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxystérols et méthodes d'utilisation associées
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
JP2019524772A (ja) 2016-08-02 2019-09-05 ヴァージニア コモンウェルス ユニバーシティ ５−コレステン−３，２５−ジオール，３−サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
CA3041077A1 (fr) 2016-10-18 2018-04-26 Sage Therapeutics, Inc. Oxysterols et leurs procedes d'utilisation
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4976857A (fr) * 1972-12-06 1974-07-24
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US4217288A (en) * 1977-03-24 1980-08-12 Wisconsin Alumni Research Foundation Anti-vitamin D compounds
JPS61254599A (ja) * 1985-05-07 1986-11-12 Sumitomo Pharmaceut Co Ltd コレステロ−ルのフツ素誘導体
IL105050A0 (en) * 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
IT1255241B (it) * 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
JP2002543216A (ja) * 1999-04-30 2002-12-17 アーチ ディベロップメント コーポレイション ステロイド誘導体
PT1392713E (pt) * 2001-05-03 2008-01-25 Univ Chicago ''agonistas de receptores x hepáticos''

Also Published As

Publication number Publication date
WO2003039480A2 (fr) 2003-05-15
JP2005508368A (ja) 2005-03-31
WO2003039480A3 (fr) 2003-06-19
TW200300078A (en) 2003-05-16
EP1450816A2 (fr) 2004-09-01
EP1450816A4 (fr) 2008-02-13

Similar Documents

Publication Publication Date Title
US20070197484A1 (en) Method of treating disorder related to high cholesterol concentration
CA2466033A1 (fr) Methode de traitement de troubles lies a un taux de cholesterol eleve
US20040014734A1 (en) Farnesoid X-activated receptor agonists
US7078396B2 (en) Method of treating disorder related to high cholesterol concentration
US7012069B2 (en) Liver X receptor agonists
CA2470703C (fr) Produits pharmaceutiques oraux renfermant 17.beta.-estradiol-3-alcanoate inferieur, procede d'administration et de preparation associes
US8246984B2 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
US20060051406A1 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
CA2274779A1 (fr) Composes aminosterol-esters
DK165839B (da) Tigogenin-cellobiosidforbindelser, farmaceutiske praeparater, der indeholder forbindelserne, anvendelse af forbindelserne til fremstilling af et farmaceutisk praeparat samt fremgangsmaade til fremstilling af forbindelserne
JP2005533810A (ja) 新規な抗コレステロール組成物及びその使用方法
NZ289793A (en) Estra-1,3,5(10)-triene derivatives, preparation and pharmaceutical compositions thereof
JP2563587B2 (ja) 新規なエステル
GB2363984A (en) Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
AU2002356919B2 (en) Method of treating disorder related to high cholesterol concentration
DE68911509T2 (de) 26-aminocholesterol und derivate und analoge davon bei der regulierung der cholesterolanhäufung in den körpergefässen.
AU2002356919A1 (en) Method of treating disorder related to high cholesterol concentration
CA3121410C (fr) Medicament contenant un ligand specifique ciblant le foie et un agoniste du recepteur des hormones thyroidiennes
CZ86296A3 (en) Novel urethane-containing aministeroidal compounds and pharmaceutical composition containing thereof
CZ299676B6 (cs) 7-Hydroxyepiandrosteron s neuroprotektivním úcinkem
WO2014117699A1 (fr) Utilisation de dérivé de protopanoxadiol et de dérivé de protopanaxatriol dans la préparation de médicament
AU2006231451A1 (en) Use of spirostenols to treat mitochondrial disorders
CN115212194A (zh) 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead